Thermo Fisher 3Q26: Timing is everything (or at least, a large part of the revenue beat)

Thermo Fisher reported 3Q26 sales of $12.1B, 1.6% above consensus, with 9.1% reported and 6% organic growth versus consensus of 4.2% and guidance of 4%; adjusted EPS of $6.68 beat by 4.3%. However, the beat was driven in large part by timing: Laboratory Products and Biopharma Services delivered 10% organic growth, with management acknowledging that pharma services strength was largely a timing element between 3Q and 4Q, and the company maintained its 4% organic guide for 4Q. Life Sciences Solutions missed meaningfully with just 1% organic growth versus 4% consensus, suggesting biotech- and A&G-exposed businesses (biosciences, genetic sciences) are still negative and bioprocessing growth may moderate beyond 3Q. Pharma/biotech and industrial/applied both grew HSD, China grew LDD with sequential improvement, and academic/government was flat. FY26 guidance was raised to $47.7-48.2B in revenue and $25.13-25.43 in adjusted EPS. We maintain our Market-Perform rating and raise our price target